You just read:

Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis

News provided by

Cancer Prevention Pharmaceuticals, Inc.; Mallinckrodt plc

May 07, 2019, 06:00 ET